tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

INmune Bio Releases Video on Alzheimer’s Trial Results

Story Highlights
INmune Bio Releases Video on Alzheimer’s Trial Results

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Inmune Bio ( (INMB) ) just unveiled an update.

On July 29, 2025, INmune Bio announced the release of a video detailing findings from their Phase 2 MINDFuL trial, which evaluates XPro™, a novel soluble TNF inhibitor, in treating early-stage Alzheimer’s disease. The video, published on the company’s YouTube channel after the Alzheimer’s Association International Conference, highlights the trial’s promising results in slowing cognitive decline by targeting neuroinflammation, offering significant insights for patients, clinicians, and investors interested in Alzheimer’s therapies.

The most recent analyst rating on (INMB) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.

Spark’s Take on INMB Stock

According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.

Inmune Bio’s overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.

To see Spark’s full report on INMB stock, click here.

More about Inmune Bio

INmune Bio Inc. is a publicly traded clinical-stage biotechnology company focused on developing treatments targeting the innate immune system to combat diseases. The company operates three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, which aims to neutralize soluble TNF involved in diseases like Alzheimer’s and depression; the Natural Killer Cell Priming Platform, which includes INKmune® for cancer treatment; and CORDStrom™, a mesenchymal stromal/stem cell platform for conditions like recessive dystrophic epidermolysis bullosa.

Average Trading Volume: 2,869,612

Technical Sentiment Signal: Sell

Current Market Cap: $77.36M

See more data about INMB stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1